表紙
市場調查報告書

花生過敏:全球疾病負擔和治療前景(Palforzia)

Peanut Allergy: Outlook on Global Disease Burden and Therapies (Palforzia)

出版商 BCC Research 商品編碼 967910
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
花生過敏:全球疾病負擔和治療前景(Palforzia) Peanut Allergy: Outlook on Global Disease Burden and Therapies (Palforzia)
出版日期: 2020年10月26日內容資訊: 英文 51 Pages
簡介

本報告調查了全球花生過敏市場,並提供了有關花生過敏的經濟影響,市場前景,增長因素,PALFORZIA和新療法的概述,現貨供應,主要公司概況等信息。

目錄

第1章簡介

第2章摘要

第3章概述

  • 花生過敏概述
  • 病因與病理生理
  • 病因
  • 病理生理學
  • 花生過敏的診斷
  • 歷史
  • 皮膚點刺測試(SPT)
  • 特定IgE(sIgE)
  • 組件分解診斷(CRD)
  • 口服食品挑戰
  • 等溫球活化試驗
  • 流行病學

第4章未滿足的需求

  • 花生過敏管理中當前未滿足的需求
  • 新療法:免疫療法
  • 意外/意外的過敏原暴露

第5章花生過敏的經濟影響

  • 花生過敏的負擔
  • 直接醫療費用和間接費用
  • 生活質量
  • 當前和未來對花生過敏的管理:對管理式護理的影響
  • 口服免疫療法的經濟分析
  • OIT的障礙

第6章巴勒斯坦:概述和市場前景

  • 藥物概述
  • 科學總結
  • 作用機理
  • 安全性和有效性治療試驗
  • 有害影響
  • 劑量,管理和成本
  • 風險評估和緩解策略
  • PALFORZIA的當前狀態
  • 法規
  • 商業化
  • 市場分析
  • 花生過敏的發生率
  • 家長角色
  • 過敏者的作用
  • 付款人的角色
  • 龐大的潛在市場
  • 銷售開始曲線

第7章花生過敏預防指南

  • 澳大利亞
  • 美國和加拿大

第8章新療法

  • Viaskin Peanut: DBV Technologies
  • CA002: Camallergy
  • PRT100: ProTA Therapeutics
  • Dupixent (Dupilumab): Regeneron

第9章監管結構

  • 美國法規
  • 歐洲法規
  • 日本規定

第10章 公司檔案

  • AIMMUNE THERAPEUTICS INC.
  • ALERE INC.
  • ALLERGAN PHARMACEUTICALS
  • ALK-ABELLO A/S
  • ALLERGOPHARMA
  • ANI BIOTECH OY
  • BECKMAN COULTER/DANAHER
  • DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
  • GLAXOSMITHKLINE
  • HITACHI CHEMICAL DIAGNOSTICS INC.
  • JUBILANT HOLLISTERSTIER
  • LABORATORY CORP. OF AMERICA HOLDINGS
  • LINCOLN DIAGNOSTICS INC.
  • QUEST DIAGNOSTICS
  • SIEMENS HEALTHCARE
  • SMARTPRACTICE DENMARK
  • TARO PHARMACEUTICAL INDUSTRIES
  • TERUMO MEDICAL CORP.
目錄
Product Code: PHM242A

Highlights:

The objective of this study is to provide an overview of the current and future market dynamics of the peanut allergy treatment market. This report explores the key drivers, management of peanut allergy, epidemiology, economic burden, and includes an overview of PALFORZIA, a new peanut allergen treatment. The key players of peanut allergy management are also discussed in the report.

This report highlights current and future market potential for PALFORZIA, with an emphasis on the epidemiological and economic burden of peanut allergy.

Report Scope:

The scope of this report includes an overview on peanut allergy management in comparison with Palforzia.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers of Palforzia immunotherapy.

This report provides a brief explanation of peanut allergy disorder with regional prevalence rates; discusses the different types of diagnostic tests and their applicability in diagnosing various allergens; and provides an overview of the growing immunotherapy market. This report organizes information from diverse sources into a cohesive package that includes -

  • A section on diagnostic products such as skin prick tests, specific IgE tests and oral food challenge tests.
  • An overview section on guidelines for the prevention of peanut allergy.
  • Specific chapters that focus on unmet needs, economic burden, emerging therapies, and regulatory structure.
  • A company profiles section that provides background information on companies active in the diagnostic and treatment arenas is also included.

Report Includes:

  • An overview of the global market for peanut allergy
  • Analysis of current and future market dynamics of peanut allergy market and identification of key drivers, restraints and opportunities
  • Coverage of disease background and epidemiology and discussion on disease burden of peanut allergy
  • Discussion on technological, regulatory and competitive elements as well as economic trends affecting the future marketplace and pipeline analysis of new products
  • Evaluation of current market trends, market size, market forecast and market share analysis of the key companies of the industry and their key market strategies
  • Profiles of major players of the industry, including Beckman Coulter Inc., GlaxoSmithKline and Hitachi Chemical Diagnostics Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology
  • Information Sources
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary

Chapter 3: Overview

  • Introduction to Peanut Allergy
  • Etiology and Pathophysiology
  • Etiology
  • Pathophysiology
  • Diagnosis of Peanut Allergy
  • History
  • Skin Prick Test (SPT)
  • Specific IgE (sIgE)
  • Component-Resolved Diagnosis (CRD)
  • Oral Food Challenge
  • The Basophil Activation Test
  • Epidemiology

Chapter 4: Unmet Needs

  • Current Unmet Needs in Managing Peanut Allergies
  • What We Know
  • Unmet Needs
  • Emerging Treatments: Immunotherapies
  • What We Know
  • Unmet Needs
  • Unintentional and Casual Exposures
  • What We Know
  • Unmet Needs

Chapter 5: The Economic Impact of Peanut Allergies

  • Burden of Peanut Allergies
  • Direct Medical and Indirect Costs
  • Quality of Life
  • Current and Future Management of Peanut Allergies: Implications for Managed Care
  • Economic Analysis of Oral Immunotherapy
  • Barriers to OIT

Chapter 6: PALFORZIA: Overview and Market Outlook

  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials on Safety and Efficacy
  • Adverse Effects
  • Dosage, Administration and Cost
  • Risk Evaluation and Mitigation Strategy
  • Current Status of PALFORZIA
  • Regulatory
  • Commercialization
  • Market Analysis
  • Incidence of Peanut Allergy
  • The Role of Parents
  • The Role of Allergists
  • The Role of Payers
  • Large Addressable Market
  • Sales Launch Curve

Chapter 7: Peanut Allergy Prevention Guidelines

  • Australia
  • U.S. and Canada
  • Addendum Guideline 1
  • Addendum Guideline 2
  • Addendum Guideline 3

Chapter 8: Emerging Therapies

  • Viaskin Peanut: DBV Technologies
  • Product Description
  • Clinical and Regulatory Activities
  • CA002: Camallergy
  • Product Description
  • Clinical and Regulatory Activities
  • PRT100: ProTA Therapeutics
  • Product Description
  • Clinical and Regulatory Activities
  • Dupixent (Dupilumab): Regeneron
  • Product Description
  • Clinical and Regulatory Activities

Chapter 9: Regulatory Structure

  • Regulations in U.S.
  • New Drug Approval
  • The FDA Modernization Act of 1997
  • Fast Track Status
  • Special Protocol Assessments
  • New Surveillance and Safety Requirements
  • Medicare
  • Regulations in Europe
  • Pricing and Reimbursement
  • Regulations in Japan

Chapter 10: Company Profiles

  • AIMMUNE THERAPEUTICS INC.
  • ALERE INC.
  • ALLERGAN PHARMACEUTICALS
  • ALK-ABELLO A/S
  • ALLERGOPHARMA
  • ANI BIOTECH OY
  • BECKMAN COULTER/DANAHER
  • DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
  • GLAXOSMITHKLINE
  • HITACHI CHEMICAL DIAGNOSTICS INC.
  • JUBILANT HOLLISTERSTIER
  • LABORATORY CORP. OF AMERICA HOLDINGS
  • LINCOLN DIAGNOSTICS INC.
  • QUEST DIAGNOSTICS
  • SIEMENS HEALTHCARE
  • SMARTPRACTICE DENMARK
  • TARO PHARMACEUTICAL INDUSTRIES
  • TERUMO MEDICAL CORP.

List of Tables

  • Table 1: Target System Involvement in the Presentation of Peanut Allergy
  • Table 2: Characteristics of Peanut Allergens
  • Table 3: Estimated Prevalence of Peanut Allergy Cases in Eight Major Markets, Through 2025
  • Table 4: Summary of Unmet Needs in Peanut Allergy
  • Table 5: Direct Medical Costs of Childhood Food Allergy
  • Table 6: Out-of-Pocket Costs* of Childhood Food Allergy
  • Table 7: Summary of Addendum Guidelines for Prevention of Peanut Allergy
  • Table 8: Alere's Product Portfolio
  • Table 9: Allergan's Product Portfolio
  • Table 10: ALK-Abello's Product Portfolio
  • Table 11: Allergopharma's Product Portfolio
  • Table 12: Ani Biotech Oy's Product Portfolio
  • Table 13: Beckman Coulter's Product Portfolio
  • Table 14: Cortez Diagnostics' Product Portfolio
  • Table 15: GlaxoSmithKline's Product Portfolio
  • Table 16: Hitachi Chemical Diagnostics' Product Portfolio
  • Table 17: Jubilant HollisterStier's Product Portfolio
  • Table 18: LabCorp's Product Portfolio
  • Table 19: Lincoln Diagnostics' Product Portfolio
  • Table 20: Quest Diagnostics' Product Portfolio
  • Table 21: Siemens Healthcare's Product Portfolio
  • Table 22: SmartPractice Denmark's Product Portfolio
  • Table 23: Terumo Medical's Products Portfolio

List of Figures

  • Figure 1: Pathophysiology of Peanut Allergy
  • Figure 2: Claim Lines with Diagnoses of Peanut Allergy and Anaphylactic Reaction to Peanuts, by Age Group, 2007-2016